Current Management Strategies of Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections.

Difficult-to-treat resistant (DTR) Pseudomonas aeruginosa is an important cause of severe health care-associated infections and is associated with high morbidity and mortality. Its complex resistance mechanisms compromise the efficacy of traditional therapies and make treatment increasingly difficult. Although new active therapeutic options such as ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam and cefiderocol are currently available, lack of randomized control trials, drug access limitations, and emerging resistance have a negative impact on the management of these infections. This review discusses the mechanisms of resistance, molecular epidemiology, clinical management, and current and future therapeutic strategies for DTR P aeruginosa infections.